Investigating how gut bacteria affect lymphoma treatment outcomes and immune response
Official title: A prospective evaluation of the gut microbiome as a mediator of lymphoma treatment outcome and systemic immunity
Funded at New York University School of Medicine · NIH-11015859 · Data updated 2026-11-12
This study is looking at how the bacteria in your gut might affect how well treatment works for people with diffuse large B-cell lymphoma, and it hopes to find ways to personalize therapies based on your unique gut health.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | New York University School of Medicine NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | February 24, 2022 |
| Project end | January 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $700,561 |
| NIH project number | 5R01CA269617-04 |
| Project ID | NIH-11015859 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with diffuse large B-cell lymphoma who are about to begin treatment.
✕Less likely to help
Patients with lymphoma types other than diffuse large B-cell lymphoma may not benefit from this research.
What this research studies
This research explores the relationship between the gut microbiome and the treatment outcomes of patients with diffuse large B-cell lymphoma (DLBCL). By analyzing stool samples from 300 patients before, during, and after treatment, the study aims to understand how the composition of gut bacteria influences the body's immune response to lymphoma. The research employs advanced sequencing techniques to identify specific gut microbiome signatures that may correlate with treatment success or failure. This could lead to new strategies for improving lymphoma therapies based on individual microbiome profiles.
Why it matters
Potential benefit: If successful, this research could lead to personalized treatment approaches that enhance the effectiveness of lymphoma therapies.
How similar studies have gone: Previous research has shown promising results in understanding the role of the gut microbiome in cancer treatment outcomes, suggesting that this approach could yield valuable insights.
Where this research is happening
-
New York University School of Medicine
New York, United States Active
Researchers
- Principal investigator: Diefenbach, Catherine Sibyl — New York University School of Medicine
- Study coordinator: Diefenbach, Catherine Sibyl
Related research
Other NIH-funded projects on the same topics.
-
Gut bacteria and treatment outcomes in lymphoma
Seeing whether the mix of gut bacteria relates to treatment success and immune responses in people with diffuse large B‑cell lymphoma.
-
Combining radiation, CAR‑T (CART‑19), and gut microbiome changes to treat B‑cell lymphoma
This project uses radiation, CART‑19 cell therapy, and a short course of oral vancomycin to try to improve outcomes for people with B‑cell lymphoma.
-
Combining radiation therapy, CART-19 therapy, and gut microbiome changes to treat lymphoma
This study is exploring a new way to treat lymphoma by using a combination of radiation therapy, a special immune treatment called CART-19, and an antibiotic to adjust the gut bacteria, all aimed at helping your body fight the cancer better.
-
Multi-agent AI to annotate enzymes in the human gut microbiome
A team at a major university will build an AI system that automatically curates and labels the functions of enzymes in the human gut microbiome to speed up understanding their health effects.
-
Understanding why Black and Hispanic Hodgkin lymphoma patients have worse survival
A patient-centered study to uncover social and care factors that contribute to lower survival among Black and Hispanic people with Hodgkin lymphoma across all ages.
-
Mapping how gut bacteria transform drugs
Scientists will study how the gut microbiome changes thousands of drugs into new forms, which could affect how well a medicine works or whether it causes side effects.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.